摘要
目的 :观察吉西他滨为主联合化疗方案治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法 :36例晚期非小细胞肺癌 ,2 0例采用吉西他滨 1.6 g ,第 1、8、15天 ,DDP 80mg m2 ,第 1天 ;16例采用吉西他滨 1.6 g ,第1、8、15天 ,紫杉醇 6 0mg ,第 1、8、15天。两方案均 4周重复 ,3周期以上评价疗效。 结果 :36例中CR 1例 ,PR 17例 ,SD 14例 ,PD 4例 ,CR +PR 18例 ,有效率 5 0 %,初治 2 0例中CR +PR 11例 ,有效率 5 5 %,复治 16例中CR +PR 7例 ,有效率 43.8%。吉西他滨 +DDP组 (其中 19例为初治 ) ,CR 1例 ,PR 10例 ,有效率 5 5 %。吉西他滨 +紫杉醇组 (其中 15例为复治 )CR +PR 7例 ,有效率 46 .7%。毒副反应主要为骨髓抑制和消化道反应 ,Ⅲ—Ⅳ度粒细胞下降 12例 ,占 33.3%,Ⅱ—Ⅲ度血小板下降 7例 ,占 19.4%,Ⅲ—Ⅳ度消化道反应 8例 ,占 2 2 .2 %。Ⅱ度肝功能损害 2例。结论 :吉西他滨为主联合化疗方案治疗晚期非小细胞肺癌有较好疗效 ,毒副反应可耐受 ,特别是吉西他滨 +紫杉醇治疗复治非小细胞肺癌有较高疗效 ,值得临床进一步观察。
Purpose:To investigate clinical effects and side reactions of advanced NSCLC by combined chemotherapy base on gemcitabine. Methods:36 cases of advanced NSCLC were divided into two groups: Group 1, 20 cases were treated by gemcitabine 1.6 g at d1,d8,d15 and 80mg/m 2 DDP at d1; Group 2,16 cases were treaded by gemcitabine 1.6 g and paclitaxel 60 mg at d1,d8,d15.Both groups were repeated every 4 weeks and clinical effects were evaluated after 3 cycles.Results:CR 1 case, PR 17 cases, SD 16 cases, PD 2 cases and CR+PR 18 cases (response rate 50 0%) in 36 cases observed. In 20 cases primary treatments:CR+PR 11cases (response rate 55 0%);In 16 cases re-treatments: CR+ PR 7 cases (response rate 43.75%); In 15 cases of advanced NSCLC re-treated by gemcitabine combined with paclitaxel: CR+PR 7 cases (response rate 46.7%). Side reaction: most cases showed bone marrow suppression and symptoms of gastrointestinal side-effects, which included 12 cases of Ⅲ-Ⅳ grades leukocytopenia (33.3%),7 cases of Ⅱ-Ⅲ grades soterocytopenia (19.4%),8 cases of Ⅲ-Ⅳ grades symptoms of gastrointestinal side-effects (22.2%),2 cases of Ⅱ grades abnormal liver function.Conclusions:Better clinical effects have been achieved in the therapy of advanced NSCLC by combined methods based on gemcitabine and side-reactions are tolerable;Nice effects were obtained in the re-treatment of NSCLC by gemcitabine combined with paclitaxel.It is valuable to investigate its Clinical effects more deeply.
出处
《中国癌症杂志》
CAS
CSCD
2001年第6期530-531,共2页
China Oncology
关键词
吉西他滨
联合化疗
非小细胞肺癌
gemcitabine
combination chemotherapy
non-small-cell lung cancer
